2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：燕金元 主管会计工作负责人：许薇 会计机构负责人：胡淑吟 编制单位：广东宝莱特医用科技股份有限公司 单位：万元 | 非经营性 | | 占用方与上市公 | 上市公司核算的 | 2025 年期初 | 2025 年半年度 | 2025 年半年度 | 2025 年半年度 | 2025 年 6 | 月 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用方名称 | | | 占用资金余 | 占用累计发生金 | 占用资金的利 | 偿还累计发生 | 期末占用资金 | | | 占用性质 | | 资金占用 | | 司的关联关系 | 会计科目 | 额 | 额（不含利息） | 息（如有） | 金额 | 余额 | | 原因 | | | 控股股 | | | | | | | | | | | | | 东、实际 | | | | | | | | | | | | | 控制人及 | — | — | — | — | — | — | — | — ...

债券代码：123065 债券简称：宝莱转债 证券代码：300246 证券简称：宝莱特 公告编号：2025-056 3、会议召开的合法、合规性：经广东宝莱特医用科技股份有限公司（以下 简称"公司"）第九届董事会第二次会议审议通过，决定召开 2025 年第三次临 时股东会，召集程序符合《中华人民共和国公司法》和《公司章程》等的规定。 4、会议召开日期和时间： （1）现场会议召开时间：2025 年 9 月 2 日（星期二）14:30 （2）网络投票时间如下： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 2 日 9:15-9:25，9:30-11:30，13:00-15:00； 广东宝莱特医用科技股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、会议召集人：广东宝莱特医用科技股份有限公司董事会 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体 时间为：2025 年 ...

债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日以通讯表决及现场会议相结合的方式召开第九届董事会第二次会议，会议通知 于 2025 年 8 月 5 日以电子邮件、电话及传真方式送达，公司董事会共有董事九 名，参与表决的董事共九名，符合《公司法》和《公司章程》的规定。 证券代码：300246 证券简称：宝莱特 公告编号：2025-051 | 证券代码：300246 | 证券简称：宝莱特 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：123065 | 债券简称：宝莱转债 | | （以上议案同意 9 票，弃权 0 票，反对 0 票） 三、 审议通过了关于拟续聘会计师事务所的议案 公司董事会同意续聘致同会计师事务所（特殊普通合伙）为公司2025年度财 务报告及内部控制审计机构，聘期一年，本议案已经董事会审计委员会审议通过。 本事项需提交公司 ...

广东宝莱特医用科技股份有限公司 2025 年半年度报告全文 广东宝莱特医用科技股份有限公司 2025 年半年度报告 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人燕金元、主管会计工作负责人许薇及会计机构负责人(会计主 管人员)胡淑吟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本公司请投资者阅读本报告全文，并特别注意公司在本报告中详细阐述了 未来可能发生的有关风险因素及对策，详见"第三节 管理层讨论与分析"之 "十、公司面临的风险和应对措施"。敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2025-054 2025 年 8 月 16 日 1 广东宝莱特医用科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 2 | | | | 第一节 重要提示、目录和释义 | 2 | | --- | --- | | 第二节 公司简介和主要财务指标 | 6 | | 第三节 管理层讨论与分析 | 9 | | ...

Core Viewpoint - Baolait (300246) experienced a decline in stock price, closing at 9.49 yuan, down 3.65% as of August 14, 2025, with significant net outflow of funds [1] Financial Performance - For Q1 2025, Baolait reported total revenue of 248 million yuan, a year-on-year decrease of 7.17% - The net profit attributable to shareholders was 14.45 million yuan, showing a year-on-year increase of 298.35% - The non-recurring net profit was 338,800 yuan, up 105.49% year-on-year - Current ratio stood at 2.278, quick ratio at 1.856, and debt-to-asset ratio at 45.06% [1] Investment and Business Activities - Baolait has invested in 21 companies and participated in 966 bidding projects - The company holds 58 trademark registrations and 330 patents, along with 179 administrative licenses [2]

Industry Overview - On August 14, the medical device industry experienced a decline of 2.45% with a net outflow of 1.74 billion yuan in principal funds [1] - Among the component stocks, 13 increased while 87 decreased [1] Major Fund Outflows - The companies with the highest net outflows of principal funds included: - Kehua Bio (29.96 million yuan) - Baolait (29.32 million yuan) - Shangrong Medical (28.74 million yuan) - Weisi Medical (26.93 million yuan) - ST Kelly (26.25 million yuan) [1] Notable Stock Performance - Key stocks with significant movements included: - Sainuo Medical: Latest price 30.43, up 3.05%, with a net inflow of 164 million yuan (7.25% of total) [1] - Botao Bio: Latest price 45.13, up 19.99%, with a net inflow of 543.74 thousand yuan (12.47% of total) [1] - Yuyue Medical: Latest price 35.67, down 0.17%, with a net inflow of 49.30 thousand yuan (12.91% of total) [1] - Kefu Medical: Latest price 40.58, up 6.99%, with a net inflow of 470.40 thousand yuan (14.3% of total) [1] - Huatai Medical: Latest price 290.99, down 2.03%, with a net inflow of 297.47 thousand yuan (9.99% of total) [1] - Aohua Endoscopy: Latest price 49.14, down 7.79%, with a net inflow of 2363.53 thousand yuan (10.09% of total) [1] - Meihua Medical: Latest price 20.94, up 3.05%, with a net inflow of 2316.72 thousand yuan (4.81% of total) [1] - Wanfu Bio: Latest price 24.28, down 0.92%, with a net inflow of 184.26 thousand yuan (5.48% of total) [1] - Zhijiang Bio: Latest price 25.24, up 4.87%, with a net inflow of 1420.31 thousand yuan (5.07% of total) [1] - Mairande: Latest price 51.64, up 1.06%, with a net inflow of 1335.64 thousand yuan (2.42% of total) [1]

Group 1 - The core viewpoint of the news is that Baolait (300246) has experienced a decline in stock price and a mixed performance in its latest financial results, indicating potential challenges ahead [1][3]. - As of August 13, 2025, Baolait's stock closed at 9.85 yuan, down 1.89%, with a turnover rate of 9.17% and a trading volume of 193,700 hands, amounting to 191 million yuan [1]. - The net outflow of main funds today was 31.4 million yuan, accounting for 16.43% of the transaction amount, with significant outflows from large orders [1]. Group 2 - For the first quarter of 2025, Baolait reported total operating revenue of 248 million yuan, a year-on-year decrease of 7.17%, while net profit attributable to shareholders was 14.4 million yuan, a year-on-year increase of 298.35% [1]. - The company has a current ratio of 2.278, a quick ratio of 1.856, and a debt-to-asset ratio of 45.06%, indicating a relatively healthy liquidity position [1]. - Baolait has made investments in 21 companies, participated in 965 bidding projects, and holds 58 trademark registrations and 329 patents, along with 179 administrative licenses [2].

中证鹏元资信评估股份有限公司 中证鹏元公告【2025】387 号 中证鹏元关于关注广东宝莱特医用科技股份有限公司完成 换届选举及聘任高级管理人员和其他相关人员的公告 中证鹏元资信评估股份有限公司（以下简称"中证鹏元"）对广 东宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"， 证券代码：300246.SZ）及其发行的下述债券开展评级。除评级委托 关系外，中证鹏元及评级从业人员与公司不存在任何足以影响评级行 为独立、客观、公正的关联关系。 | | | 主体等级 | 债项等级 | 评级展望 | | --- | --- | --- | --- | --- | | 债券简称 宝莱转债 | 上一次评级时间 2025 年 6 月 13 日 | AA- | 上一次评级结果 AA- | 负面 | 根据公司于 2025 年 8 月 1 日公告的《广东宝莱特医用科技股份 有限公司关于公司董事会完成换届选举及聘任高级管理人员和其他 相关人员的公告》，公司已顺利完成董事会的换届选举及高级管理人 员和其他相关人员的换届聘任。公司第九届董事会由 9 名董事组成， 其中非独立董事 6 名（含 1 名职工代表董事），独立董事 3 名 ...

Core Viewpoint - The blood oxygen monitor concept sector has shown a positive performance, with a 1.62% increase, ranking fifth among concept sectors in terms of growth [1][2]. Group 1: Sector Performance - As of the close on August 7, the blood oxygen monitor concept sector saw 15 stocks rise, with Jinghua Microelectronics, Aipeng Medical, and Baolait leading the gains at 14.41%, 8.45%, and 3.51% respectively [1]. - The sector experienced a net inflow of 39 million yuan from main funds, with nine stocks receiving net inflows, and six stocks exceeding 10 million yuan in net inflow [2]. Group 2: Key Stocks - Jinghua Microelectronics had the highest net inflow of main funds at 53.64 million yuan, followed by Jiuan Medical and Kangtai Medical with net inflows of 47.85 million yuan and 47.62 million yuan respectively [2][3]. - The net inflow ratios for Jinghua Microelectronics, Kangtai Medical, and Jiuan Medical were 17.04%, 11.20%, and 7.14% respectively, indicating strong investor interest [3].

Group 1 - The company Baolite announced on the evening of August 1 that its ninth board of directors held its first meeting and approved multiple proposals, including the election of the chairman of the ninth board of directors [2]